Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years

Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms

Prospective Sexual Function Study for BPH Subjects

Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia

Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement

Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study

Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

ALF-ONE : ALFuzosin ONcE Daily

Once Daily Given Alfuzosin in the Treatment of BPH

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients

Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction

Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia

Use of Alfuzosin in Stone Treatment With ESWL

ALF-STONE: Alfuzosin in Uretheric Stones

Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology

Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects

Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

Alfuzosin Versus Placebo in Acute Urinary Retention

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH

Clinical Trial in Males With BPH (Enlarged Prostate)

Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

Alfuzosin for Treating Acute Urinary Retention

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples

Bioequivalence - Duodart Against Avodart & Omnic

A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia

Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.

Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects

A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.

SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin

SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin

A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031